FibroGen to Present at Jefferies Healthcare Conference

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) announced that CEO Enrique Conterno will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 PM EDT. A live audio webcast will be available on the company's Investors webpage, with a replay accessible for up to 30 days. FibroGen focuses on developing innovative therapeutics, including pamrevlumab for conditions like idiopathic pulmonary fibrosis and roxadustat for anemia linked to chronic kidney disease. The company is also expanding into immuno-oncology and autoimmune research.

SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT.

A live audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of potential first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.

Contact:
FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com

Media:
Meichiel Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com

FAQ

When will FibroGen CEO Enrique Conterno speak at the Jefferies Healthcare Conference?

Enrique Conterno will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 PM EDT.

Where can I watch the FibroGen conference webcast?

The live audio webcast of the conference will be available on the FibroGen Investors webpage at www.fibrogen.com.

How long will the FibroGen conference replay be available?

A replay of the FibroGen conference will be available for approximately 30 days.

What is the primary focus of FibroGen's research and development?

FibroGen is focused on developing therapeutics for unmet medical needs, including treatments for idiopathic pulmonary fibrosis and anemia.

What drug candidates is FibroGen currently developing?

FibroGen is developing pamrevlumab for idiopathic pulmonary fibrosis and roxadustat for various types of anemia.